曲妥珠单抗
抗体-药物偶联物
靶向治疗
抗体疗法
医学
结合
抗体
癌症
癌症研究
计算生物学
生物
内科学
单克隆抗体
免疫学
乳腺癌
数学分析
数学
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-06-06
卷期号:13 (8): OF3-OF3
被引量:1
标识
DOI:10.1158/2159-8290.cd-nb2023-0047
摘要
The antibody-drug conjugate trastuzumab deruxtecan shows promising activity across multiple types of HER2-expressing advanced solid tumors, including traditionally hard-to-treat malignancies, according to data from the DESTINY-PanTumor02 trial. The ongoing study may pave the way for approval of a tumor-agnostic therapy for HER2-expressing and HER2-mutated cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI